FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308385281> ?p ?o ?g. }

• W4308385281 abstract "<h3>Background</h3> After the first Immune Checkpoint Inhibitor (ICI) was approved (ipilimumab, 2011 for cancer therapy, the list of indications routinely treated with ICIs keeps increasing. In this new era of cancer immunotherapy, the major drawback of the approach is the difficulty in delivering long term benefits to a larger portion of patients. Different forms of immunotherapy used in solid tumor cancer patients seem to work better in immunologically hot tumors. To that extent, TILT-123 (an Oncolytic Adenovirus armed with TNFa and IL-2) was designed to stimulate the immune system within the tumor to enable subsequent forms of immunotherapy. After discovery and preclinical testing, the therapy was taken into clinical trials in 2020. Two years after, four Phase I clinical trials are ongoing where TILT-123 is being tested to determine its safety as monotherapy (NCT04695327), together with adoptive cell therapy using tumor-infiltrating lymphocytes (NCT04217473), and ICIs (NCT05271318, NCT05222932). <h3>Methods</h3> These phase I open-label, dose-escalation clinical trials, have the primary endpoint of establishing safety of the treatments in patients with injectable advanced refractory and recurrent solid tumors, that cannot be treated with curative intent. Safety is evaluated based on the occurrence of adverse events, impact on vital signs and safety laboratory tests. Additionally, secondary endpoints relative to the trials include efficacy of the approaches and mechanistic analyses based on biological samples, including studies on the presence and persistence of virus in different fluids and tissues, as well as, the proteomic and transcriptomic changes seen in tumors after therapy. Antitumor efficacy, according to RECIST 1.1/iRECIST/PET criteria, has been recorded in different patients. <h3>Results</h3> Interim safety data emerging from patients treated with TILT-123 (n=18 patients), provided confidence to continue dose escalation as the investigational medicinal product did not cause dose limiting toxicities. The most frequent treatment related adverse events, as judged by investigators, were fever, nausea, chills and fatigue, typically low grade according to the CTCAE v5.0. Systemic antitumor efficacy according to RECIST 1.1/iRECIST/PET criteria has been seen in several patients. Biological sample analyses demonstrate the remodeling of the tumor microenvironment towards an antitumor status, when studying the T cell presence and the immune signature within the tumor. <h3>Conclusions</h3> Preliminary data emerging from Phase I clinical trials using TILT-123, point to an adequately safe approach able to induce antitumor activity, both as monotherapy and in combination. Dose escalation continues in pursuit of a recommended dose to use in Phase II clinical trials. <h3>Acknowledgements</h3> The clinical trials reported above were made possible due to the magnificent teamwork from the trial sites and the willingness of patients to collaborate in this research. Authors are thankful to the entire Cancer Gene Therapy Group of University of Helsinki for their valuable support. Funded by TILT Biotherapeutics Ltd. <h3>Trial Registration</h3> NCT04695327, NCT04217473, NCT05271318, and NCT05222932 <h3>Ethics Approval</h3> TILT-T115: This study was approved by the Finnish National Committee on Medical Research Ethics (TUKIJA); approval number HUS/1804/2020 TILT-T215: This study was approved by the Danish National Committee on Health Research Ethics (NVK); approval number 1905760 TILT-T563: This study was approved by the Finnish National Committee on Medical Research Ethics (TUKIJA); approval number TUKIJA/405/2021 TILT-T776: This study was approved by the Finnish National Committee on Medical Research Ethics (TUKIJA); approval number TUKIJA/366/2021" @default.
• W4308385281 created "2022-11-11" @default.
• W4308385281 creator A5001247907 @default.
• W4308385281 creator A5002644565 @default.
• W4308385281 creator A5007169190 @default.
• W4308385281 creator A5011563007 @default.
• W4308385281 creator A5019145336 @default.
• W4308385281 creator A5024539974 @default.
• W4308385281 creator A5025825017 @default.
• W4308385281 creator A5029719292 @default.
• W4308385281 creator A5029723342 @default.
• W4308385281 creator A5036808328 @default.
• W4308385281 creator A5047255658 @default.
• W4308385281 creator A5062078543 @default.
• W4308385281 creator A5062191415 @default.
• W4308385281 creator A5062608835 @default.
• W4308385281 creator A5065474301 @default.
• W4308385281 creator A5073488854 @default.
• W4308385281 creator A5078315282 @default.
• W4308385281 creator A5080358452 @default.
• W4308385281 date "2022-11-01" @default.
• W4308385281 modified "2023-09-23" @default.
• W4308385281 title "715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials" @default.
• W4308385281 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0715" @default.
• W4308385281 hasPublicationYear "2022" @default.
• W4308385281 type Work @default.
• W4308385281 citedByCount "0" @default.
• W4308385281 crossrefType "proceedings-article" @default.
• W4308385281 hasAuthorship W4308385281A5001247907 @default.
• W4308385281 hasAuthorship W4308385281A5002644565 @default.
• W4308385281 hasAuthorship W4308385281A5007169190 @default.
• W4308385281 hasAuthorship W4308385281A5011563007 @default.
• W4308385281 hasAuthorship W4308385281A5019145336 @default.
• W4308385281 hasAuthorship W4308385281A5024539974 @default.
• W4308385281 hasAuthorship W4308385281A5025825017 @default.
• W4308385281 hasAuthorship W4308385281A5029719292 @default.
• W4308385281 hasAuthorship W4308385281A5029723342 @default.
• W4308385281 hasAuthorship W4308385281A5036808328 @default.
• W4308385281 hasAuthorship W4308385281A5047255658 @default.
• W4308385281 hasAuthorship W4308385281A5062078543 @default.
• W4308385281 hasAuthorship W4308385281A5062191415 @default.
• W4308385281 hasAuthorship W4308385281A5062608835 @default.
• W4308385281 hasAuthorship W4308385281A5065474301 @default.
• W4308385281 hasAuthorship W4308385281A5073488854 @default.
• W4308385281 hasAuthorship W4308385281A5078315282 @default.
• W4308385281 hasAuthorship W4308385281A5080358452 @default.
• W4308385281 hasBestOaLocation W43083852811 @default.
• W4308385281 hasConcept C121608353 @default.
• W4308385281 hasConcept C126322002 @default.
• W4308385281 hasConcept C143998085 @default.
• W4308385281 hasConcept C197934379 @default.
• W4308385281 hasConcept C203092338 @default.
• W4308385281 hasConcept C2777701055 @default.
• W4308385281 hasConcept C2780674031 @default.
• W4308385281 hasConcept C2781433595 @default.
• W4308385281 hasConcept C535046627 @default.
• W4308385281 hasConcept C71924100 @default.
• W4308385281 hasConcept C82210918 @default.
• W4308385281 hasConceptScore W4308385281C121608353 @default.
• W4308385281 hasConceptScore W4308385281C126322002 @default.
• W4308385281 hasConceptScore W4308385281C143998085 @default.
• W4308385281 hasConceptScore W4308385281C197934379 @default.
• W4308385281 hasConceptScore W4308385281C203092338 @default.
• W4308385281 hasConceptScore W4308385281C2777701055 @default.
• W4308385281 hasConceptScore W4308385281C2780674031 @default.
• W4308385281 hasConceptScore W4308385281C2781433595 @default.
• W4308385281 hasConceptScore W4308385281C535046627 @default.
• W4308385281 hasConceptScore W4308385281C71924100 @default.
• W4308385281 hasConceptScore W4308385281C82210918 @default.
• W4308385281 hasLocation W43083852811 @default.
• W4308385281 hasOpenAccess W4308385281 @default.
• W4308385281 hasPrimaryLocation W43083852811 @default.
• W4308385281 hasRelatedWork W2051146169 @default.
• W4308385281 hasRelatedWork W2055909010 @default.
• W4308385281 hasRelatedWork W2103172697 @default.
• W4308385281 hasRelatedWork W2403659214 @default.
• W4308385281 hasRelatedWork W2774483847 @default.
• W4308385281 hasRelatedWork W3083422710 @default.
• W4308385281 hasRelatedWork W4308385281 @default.
• W4308385281 hasRelatedWork W4320489657 @default.
• W4308385281 hasRelatedWork W4360993498 @default.
• W4308385281 hasRelatedWork W4361208677 @default.
• W4308385281 isParatext "false" @default.
• W4308385281 isRetracted "false" @default.
• W4308385281 workType "article" @default.